



OBJECTIVES


By January 6, 2021, 7,812,007 cases and 197,777 deaths in total have been confirmed in Brazil, suggesting that the overall death rate of COVID-19 was 2.6%. Diabetes is the most common comorbidities in adult patients infected with Severe Acute Syndrome Coronavirus 2 (SARS-CoV-2) and has been associated with increased mortality. This study analyzed the mortality of hospitalized COVID-19 patients with diabetes.


METHODS

654 patients with COVID-19, including 81 diabetic patients and 573 nondiabetic patients from March to December/2020, were registered. Administrative data from hospitalizations reimbursed by the health plan were analyzed. Dependent variable: mortality rate (MR) of both groups had the number of deaths as a numerator and the number of patients hospitalized with COVID-19 in the period as denominator. Independent variables: age and sex. The main outcome was mortality by the SARS-CoV2. Statistical: Microsoft Excel® v2010 and Qlik Sense® v13.21 were used for relative and absolute frequencies, means and standard deviation (95% confidence intervals, significance when $p < 0.05$).

RESULTS

From the total number of hospitalized COVID-19 patients, 50.6% were male and 49.4% female. The median age was 64.3 years. Approximately 12.4% of patients had diabetes. The mortality rate in diabetic patients was 28.4% and 18.0% in nondiabetic patients, with a pooled Odds Ratio of 1.81 (95% CI 1.07 – 3.07; $p < 0.05$). When comparing the rate by sex, mortality in diabetic men was higher than in women (21.1% and 17.3%, respectively; $p > 0.05$).





CONCLUSIONS

This study suggests that diabetes are associated with an increased risk of COVID-19-related in-hospital death confirming a need for close monitoring of diabetic patients during hospitalization. Increased COVID-19-related mortality usually was associated with cardiovascular and renal complications of diabetes. Diabetes requires uninterrupted treatment, so Healthcare System must take steps to ensure access to the care it needs.

REFERENCES

- 1-Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. *Diabetes Res Clin Pract.* 2020 Jul;165:108263. doi: 10.1016/j.diabres.2020.108263. Epub 2020 Jun 10. PMID: 32531325; PMCID: PMC7283049.
- 2-Boulton A. Why diabetes must not be forgotten in the global fight against COVID-19. *Diabetes Res Clin Pract.* 2020 Jul;165:108319. doi: 10.1016/j.diabres.2020.108319. PMID: 32741472; PMCID: PMC7392558.
- 3-Pontiroli AE, La Sala L, Chiumello D, Folli F. Is blood glucose or obesity responsible for the bad prognosis of COVID-19 in obesity - diabetes? *Diabetes Res Clin Pract.* 2020 Sep;167:108342. doi: 10.1016/j.diabres.2020.108342. Epub 2020 Jul 27. PMID: 32730788; PMCID: PMC7384403.
- 4-Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Holman, Naomi et al. *The Lancet Diabetes & Endocrinology*, Volume 8, Issue 10, 823 – 833
- 5-Yang, Yan et al. “The effect of diabetes on mortality of COVID-19: A protocol for systematic review and meta-analysis.” *Medicine* vol. 99,27 (2020): e20913. doi:10.1097/MD.00000000000020913